ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 562

Anti-Muscarinic Receptor 3 Antibodies – a Cross Reactive Result of Ro60 Immunization

Syed M.S. Quadri1, Biji T Kurien2, Kristi A. Koelsch3 and R. Hal Scofield4, 1Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Okalahoma City, OK, 4Oklahoma Medical Research Foundation, Oklahoma City, OK

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Auto-immunity, autoantibodies, autoantigens and autoimmune diseases, Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Sjögren's Syndrome Poster I: Translational Research

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Sjogren’s syndrome (SS) is a chronic autoimmune inflammatory disease characterized by impaired function of salivary and lacrimal glands leading to dry mouth and dry eyes. The hallmark of SS is the presence of autoantibodies against Ro and La antigens. High titers of anti-Ro60 autoantibodies have shown to correlate with severity of the disease. It is yet unclear how these antiRo60 antibodies correlate with severity. Autoantibodies against M3R are also prevalent in SS. Muscarinic receptor 3 abbr. as M3R is an end organ parasympathetic GPCR mainly present in lacrimal and salivary glands. The stimulation of M3R is well studied and is known to induce secretion in lacrimal and salivary glands and so an effect to M3R could possibly lead to a reduction in secretion.We immunized rabbits with Ro60 and found that immunization not only resulted in the formation of antibodies against Ro60 but also to 2nd and 3rd extracellular domains of the M3 receptor. The reactivity to Ro60 and M3R 2nd and 3rd extracellular domains has also shown a high correlation.

Methods:

Immunization of rabbits: NZW rabbits were immunized with 500µg of either unmodified Ro60, Smith or RNP antigen) emulsified in 0.5 ml of complete Freund’s adjuvant given I/P with subsequent boosters at days 26, 53 and 99 with a final I/V boost on day 152. The sera were collected weekly in pre and post-immunized rabbits. Ro60 and M3R experiments: Reactivity of sera towards Ro60, MAPS of M3R 2nd or 3rd extracellular domains were tested using ELISA. Seral dilution ELISA was done using dilution 1:100 to 1: 100,000 and competition ELISA by preincubating sera with either Ro60 and MAPS of 2nd ECL was done to see the specificity of antibody binding.

Results: Rabbits immunized with Ro60 developed antibodies against Ro60, M3R 2nd and 3rd ECLs in a progressive way. A positive correlation was found between both Ro60 and M3R 2nd ECL (R2 =0.66, p = <0.0001) and between Ro60 and M3R 3rd ECL(R2 =0.789, p = <0.0001) . A positive correlation was also found between M3R 2nd and 3rd ECL ELISA (R2 =0.56, p = 0.0001). Rabbits immunized with Smith and RNP antigen did not develop antibodies to any of the extracellular domains of M3R to significant levels. Seral dilution ELISA showed a sequential decline in reactivity for both the 2nd and the 3rd ECL of M3R. Competition ELISA for 2nd ECL of M3R using sera preincubated with M3R 2nd ECL showed an inhibition of 48.2% to 58.99%, sera preincubated with Ro60 showed an inhibition of 54.5 to 89.03% verifying the specific binding.

Conclusion: Previously our studies found high reactivity for M3R and Ro60 antigen in fully human recombinant monoclonal antibodies produced from plasmablasts isolated from salivary glands of SS patients and was found to be inhibitory. The subsequent step, immunization of rabbits with Ro60 also supported the same hypothesis. The rabbits immunized with Ro60 developed antibodies to M3R extracellular domains supporting the concept of cross-reactivity. Our next step is to see whether the immunization of rabbits with M3R develops anti-Ro60 antibodies. Our future studies are also aimed at passive transfer of IgGs (from Ro60 immunized rabbit sera as well as human recombinant IgGs positive for M3R and Ro) to mice to see the invivo functional consequences of this cross-reactivity.


Disclosure: S. M. S. Quadri, None; B. T. Kurien, None; K. A. Koelsch, None; R. H. Scofield, None.

To cite this abstract in AMA style:

Quadri SMS, Kurien BT, Koelsch KA, Scofield RH. Anti-Muscarinic Receptor 3 Antibodies – a Cross Reactive Result of Ro60 Immunization [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/anti-muscarinic-receptor-3-antibodies-a-cross-reactive-result-of-ro60-immunization/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-muscarinic-receptor-3-antibodies-a-cross-reactive-result-of-ro60-immunization/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology